Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16.
"We continue to advance our clinical programs and present data to the medical community demonstrating the advantages of using our urine-based molecular diagnostics in the management of various cancer types," stated Mark Erlander, Ph.D., chief scientific officer of Trovagene. "The data sets to be presented at these conferences support the clinical utility of our non-invasive cancer monitoring tests in both lung and colorectal cancers, and their ability to empower oncologists to detect and quantitatively track driver mutations to improve treatment decisions."
2015 Cancer Markers and Liquid Biopsies
June 11 2015, 11:25 a.m. PDT Oral Presentation
Early Pharmacodynamics Using Urinary ctDNA as a Putative Biomarker of Drug Response
Presenter: Mark Erlander, Ph.D., Trovagene, Inc.
Highlights: High frequency testing of circulating tumor (ct)DNA mutations in patients receiving molecularly targeted therapies can be used to determine early changes in mutation load brought about by treatment administration, in addition to tumor dynamics when used to monitor treatment response longitudinally
June 12 2015, 10:45 a.m. PDT Oral Presentation
Monitoring Urinary Circulating Tumor DNA (ctDNA) KRAS for Treatment Response in Patients with Metastatic Colorectal Cancer (mCRC)
Collaborator: Afsaneh Barzi, M.D., USC Norris Comprehensive Cancer Center
Highlights: Potential to guide treatment decisions in metastatic colorectal cancer (mCRC) patients based on ctDNA KRAS mutation dynamics
AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy
June 15, 2015, 12:30 – 3:00 p.m. CDT Poster Session
Quantitative Monitoring of EGFR Mutations in Urinary Circulating Tumor DNA Enables Non-Invasive Pharmacodynamic Assessment of Anti-EGFR Drug Response
Single Cell and Circulating Free Nucleic Acid Sequencing Session, Abstract: # 29
Collaborator: Hatim Husain, M.D., UCSD Moores Cancer Center
Highlights:
- Urine-based EGFR ctDNA assay has been shown to outperform tissue biopsy for the detection of EGFR T790M mutations in metastatic lung cancer patients
- Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy, and months before detection of cancer progression with imaging
- Tracking ctDNA in urine enables determination of response to next generation EGFR T790M inhibitors within days of initial treatment
22 pesticides found to be associated with prostate cancer incidence in the United States